COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 763 for:    dry mouth

Finger-prick Autologous Blood (FAB) for Use in Dry Mouth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03530735
Recruitment Status : Not yet recruiting
First Posted : May 21, 2018
Last Update Posted : July 27, 2018
Information provided by (Responsible Party):
Bedford Hospital NHS Trust

Brief Summary:

This is a feasibility study that will assess the efficacy of using autologous blood to treat moderate to severe dry mouth. Dry mouth has been estimated to affect up to 64.8% of the general population (Navazesh et al., 2009) and many patients that are affected by Sjögren's syndrome or have had radiation therapy to combat head or neck cancer (Navazesh et al., 2009).

The blood will be applied to the interior of the mouth by means of a mouthwash. This research poses the first potential curative treatment for dry mouth - all other current dry mouth treatments are either symptomatic or lifestyle-based.

Autologous blood has been shown to be effective in treating the epithelial surface of dry eyes. This has been attributed to the analogous growth factors in the blood to that of tears - and potentially in this case, saliva - in healing the oral epithelial surface (Herbst et al., 2004).

Condition or disease Intervention/treatment Phase
Xerostomia Xerostomia Due to Radiotherapy Xerostomia Due to Hyposecretion of Salivary Gland Other: Finger-prick Autologous Blood (FAB) Not Applicable

Detailed Description:

Fingerprick autologous blood (FAB) has been demonstrated to be effective in treating dry eye disease by inducing healing of the epithelial surface of the eye (Than et al., 2017). The epithelial layers of both the mouth and the eye require a non-vascular source of lubrication and nutrients (tears and saliva respectively). These nutrients include growth factors - naturally occurring substances capable of stimulating cellular growth. Saliva provides transforming growth factor alpha (TGF - α) (Mogi et al., 1995), epidermal growth factor (EGF) (Herbst, 2004; Marti et al., 1989), and Hepatocyte growth factor (HGF) (Amano et al., 1994) whilst tears provide EGF (Ohashi et al., 1989) amongst others (including TGF -β 1 and 2 (Gupta et al., 1996) integral to the proliferation, survival and differentiation of the oral epithelial cells (Klenkler et al., 2007). Therefore, as severe dry mouth disease (and a subsequent lack of saliva and growth factors) causes damage to the epithelial surface lining the mouth, a growth factor rich saliva substitute like FAB, should be an effective treatment for dry mouth. There is currently no study which details FAB for use in dry mouth.

Whole or parts of the three major salivary glands have been surgically transplanted or redirected to provide a replacement tear film in patients with severe dry eyes. This has been shown to be successful in both lubricating and improving eye comfort in afflicted patients (Geerling & Sieg, 2008). Since both blood and saliva have been shown to be effective as tear substitutes, it stands to reason that both tears and blood may be effective as a saliva substitute. Both tears and saliva are extraordinarily complex blood derived biological products which provide nourishment to an epithelial surface, and as such, blood should serve as a sufficiently close mimic of saliva.

Sjögren's syndrome, a chronic systemic autoimmune disease, occurs due to infiltration of secretory (exocrine) glands including the eye and mouth, resulting in dry eye and mouth respectively. FAB has been shown to be effective in treating Sjögren's induced dry eye and logically should also be an efficacious treatment for Sjögren's induced dry mouth.

Currently no curative measures for dry mouth exist. Oral dryness is managed conservatively by providing lubrication through a temporary solution such as lifestyle changes, artificial sprays, dry mouth mouthwash solutions or sialagogues (Shirlaw & Khan, 2017). There is no treatment that addresses the complexity of salivary constituents. Oral pilocarpine can be used to stimulate salivary glands at least as effectively as artificial saliva, however side effects were high including sweating, urinary frequency and vasodilation (Davies & Thompson, 2015).

Thus, FAB offers a potentially novel and better way than currently prescribed methods to treat dry mouth disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
Estimated Study Start Date : September 1, 2018
Estimated Primary Completion Date : December 1, 2019
Estimated Study Completion Date : December 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dry Mouth

Arm Intervention/treatment
Experimental: Fingerprick Autologous Blood (FAB) for Use in Dry Mouth

All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.

Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home.

Other: Finger-prick Autologous Blood (FAB)

Patients will be instructed to use FAB therapy by:

  1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.
  2. Use a diabetic lancet to prick their cleaned fingertip.
  3. Squeeze 5 drops of blood form their finger into 10ml of saline.
  4. Gargle the blood-saline mixture for 5 minutes.
  5. Swallow the blood-saline mixture.
  6. Repeat this 4 times per day.

Primary Outcome Measures :
  1. Improvement of signs of clinical dry mouth [ Time Frame: 6 months ]
    To assess improvement of signs of dry mouth using the Challachombe scale for visual identification and quantification of dry mouth

  2. Improvement of symptoms of Dry Mouth [ Time Frame: 6 months ]
    To assess improvement of signs of dry mouth using the seven item Xerostomia index.

Secondary Outcome Measures :
  1. Adherence Self Report Questionnaire to assess patient compliance [ Time Frame: 12 months ]
    We will create a questionnaire to assess patient adherence to apply fresh autologous blood during the study and after the study period has ceased. There will also be questions on patient comfort and thoughts on the application process.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Patients diagnosed with dry mouth and are on or have refused treatment e.g. spray or mouthwash

Exclusion Criteria:

  • Patients who do not have capacity to consent
  • Patients with immunodeficiency
  • Infected finger or systemic infection or on systemic antibiotics for infection
  • Patients with active microbial infection, acute herpes simplex, herpes zoster or infected mouth ulcers
  • Pregnant or breast feeding women
  • Fear of needles and unwillingness to carry out repeated finger pricks
  • Patients with frank oral ulceration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03530735

Layout table for location contacts
Contact: Anant Sharma, MBBS, FRCOphth 01234355122
Contact: Rynda Nitiahpapand, MBBS 01234355122

Sponsors and Collaborators
Bedford Hospital NHS Trust


Layout table for additonal information
Responsible Party: Bedford Hospital NHS Trust Identifier: NCT03530735    
Other Study ID Numbers: IRAS 228680
First Posted: May 21, 2018    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bedford Hospital NHS Trust:
Fingerprick Autologous Blood
Additional relevant MeSH terms:
Layout table for MeSH terms
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases